UBS Group
RLAY icon

UBS Group’s Relay Therapeutics RLAY Stock Holding History

UBS Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.5M Buy
1,094,980
+567,369
+108% +$8.24M ﹤0.01% 2652
2026
Q1 		$5.25M Buy
527,611
+231,594
+78% +$2.07M ﹤0.01% 4037
2025
Q4 		$2.5M Buy
296,017
+143,764
+94% +$1.03M ﹤0.01% 4754
2025
Q3 		$795K Sell
152,253
-20,837
-12% -$79.5K ﹤0.01% 5744
2025
Q2 		$599K Sell
173,090
-102,468
-37% -$305K ﹤0.01% 5861
2025
Q1 		$722K Sell
275,558
-67,688
-20% -$265K ﹤0.01% 5562
2024
Q4 		$1.41M Buy
343,246
+151,522
+79% +$825K ﹤0.01% 5034
2024
Q3 		$1.36M Buy
191,724
+2,404
+1% +$18K ﹤0.01% 4362
2024
Q2 		$1.23M Sell
189,320
-98,606
-34% -$674K ﹤0.01% 4218
2024
Q1 		$2.39M Buy
287,926
+101,627
+55% +$991K ﹤0.01% 3765
2023
Q4 		$2.05M Buy
186,299
+125,340
+206% +$1.06M ﹤0.01% 3797
2023
Q3 		$513K Sell
60,959
-133,738
-69% -$1.44M ﹤0.01% 4634
2023
Q2 		$2.45M Buy
194,697
+24,034
+14% +$299K ﹤0.01% 3337
2023
Q1 		$2.81M Sell
170,663
-92,437
-35% -$1.66M ﹤0.01% 3064
2022
Q4 		$3.93M Buy
263,100
+242,674
+1,188% +$4.64M ﹤0.01% 2728
2022
Q3 		$456K Sell
20,426
-44,207
-68% -$970K ﹤0.01% 4414
2022
Q2 		$1.08M Sell
64,633
-51,888
-45% -$1.11M ﹤0.01% 3670
2022
Q1 		$3.49M Buy
116,521
+22,283
+24% +$541K ﹤0.01% 2907
2021
Q4 		$2.89M Buy
94,238
+83,354
+766% +$2.63M ﹤0.01% 3394
2021
Q3 		$343K Sell
10,884
-19,727
-64% -$664K ﹤0.01% 4962
2021
Q2 		$1.12M Sell
30,611
-12,650
-29% -$417K ﹤0.01% 4089
2021
Q1 		$1.5M Buy
43,261
+34,849
+414% +$1.51M ﹤0.01% 3851
2020
Q4 		$350K Buy
8,412
+7,873
+1,461% +$356K ﹤0.01% 4865
2020
Q3 		$23K Buy
+539
New +$20.6K ﹤0.01% 6206

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

UBS Group's RLAY Position: Q2 2026 in Review

UBS Group increased its Relay Therapeutics (RLAY) stake by 108% in Q2 2026, buying an estimated $8.24M and bringing the position to 1,094,980 shares worth $20.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2652.

UBS Group first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • UBS Group held 1,094,980 shares of Relay Therapeutics worth $20.5M as of Q2 2026.
  • UBS Group bought 567,369 Relay Therapeutics shares in Q2 2026, an estimated $8.24M.
  • Relay Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2652 holding.
  • UBS Group first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.